U.S. Markets closed

Mereo BioPharma Group plc (MREO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.5329+0.0429 (+8.76%)
At close: 04:00PM EDT
0.5100 -0.02 (-4.30%)
After hours: 07:08PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4900
Bid0.5025 x 800
Ask0.5321 x 1200
Day's Range0.4900 - 0.5700
52 Week Range0.3010 - 3.7500
Avg. Volume979,570
Market Cap58.034M
Beta (5Y Monthly)1.47
PE Ratio (TTM)N/A
EPS (TTM)-0.3560
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est699.23
  • GlobeNewswire

    Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors

    LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Company’s Board of Directors, effective immediately. Dr. Mullick joins Mereo’s Board with over 20 years of experience in the pharmaceutical industry in senior leadership positions across multiple therapeutic areas and geogr

  • Benzinga

    Mereo BioPharma Shares Jump After Encouraging Alvelestat Data In Lung Disease

    Mereo BioPharma Group plc (NASDAQ: MREO) has announced topline efficacy and safety results from ASTRAEUS Phase 2 study of alvelestat (MPH-966) in severe alpha-1 antitrypsin deficiency-(AATD) associated emphysema. Emphysema is a lung disease caused by damage to the small air sacs in the lungs (alveoli). The study evaluated two different doses of alvelestat (high or low dose) or placebo over 12 weeks on three primary biomarker endpoints associated with AATD-related lung disease (AATD-LD), blood ne

  • GlobeNewswire

    Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema

    Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period Statistically significant reductions in the biomarkers Aα-val360 and desmosine at the high dose demonstrating clear impact of alvelestat on the pathogenic pathway of AATD-lung disease No safety signals were associated with alvelestat Conference Call Today at 10:30 a.m. ET LONDON and REDWOOD CITY, Calif., May 09, 2022